Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2026-05-27 Declaration of Voting R…
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 89% confidence The document is a Form 8-K filed by Shuttle Pharmaceuticals Holdings reporting the final vote results for proposals conducted at the 2026 Annual Meeting of Stockholders (e.g., election of directors, ratification of auditor, say-on-pay vote, reverse stock split authorization). This is a classic “Declaration of Voting Results & Voting Rights Announcements” reporting vote tallies. Accordingly, it matches Code DVA.
2026-05-27 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
M&A Activity Classification · 90% confidence The document is a Form 8-K “Current Report” under Item 1.01 describing the entry into a material definitive Merger Agreement (plus related financing and amendments to asset purchase agreements). It is an announcement of merger and takeover related transactions. Under our taxonomy, this falls squarely into the M&A Activity category (Code TAR).
2026-05-07 English
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
M&A Activity Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 30, 2026, by Shuttle Pharmaceuticals Holdings, Inc. The content focuses on the announcement of a material definitive agreement, specifically a Merger Agreement between Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. The document details the terms of the merger, transaction consideration, representations and warranties, covenants, and other merger-related information. There is no indication that this is a full annual or quarterly report, audit report, earnings release, or other financial statement. Instead, it is a regulatory filing announcing a significant corporate transaction (merger). According to the filing definitions, announcements related to merger proposals or takeover bids fall under the category 'M&A Activity' (Code: TAR). Therefore, this document should be classified as M&A Activity.
2026-05-01 English
ARS - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
Annual Report
2026-04-20 English
DEF 14A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
Proxy Solicitation & Information Statement
2026-04-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.